ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 279 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 1.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $781 | -64.6% | 48,085 | -59.8% | 0.01% | -70.6% |
| Q1 2024 | $2,209 | -61.7% | 119,492 | -56.8% | 0.02% | -69.1% |
| Q3 2023 | $5,769 | +210.0% | 276,829 | +179.9% | 0.06% | +266.7% |
| Q1 2023 | $1,861 | -75.0% | 98,890 | -78.8% | 0.02% | -86.1% |
| Q4 2022 | $7,432 | -99.3% | 466,843 | +665.4% | 0.11% | +730.8% |
| Q3 2022 | $998,000 | +58.2% | 60,997 | +36.2% | 0.01% | +62.5% |
| Q2 2022 | $631,000 | -64.7% | 44,773 | -39.3% | 0.01% | -65.2% |
| Q1 2022 | $1,786,000 | +142.7% | 73,761 | +144.3% | 0.02% | +187.5% |
| Q2 2021 | $736,000 | +9.9% | 30,188 | +16.3% | 0.01% | -20.0% |
| Q1 2021 | $670,000 | -77.4% | 25,959 | -53.3% | 0.01% | -65.5% |
| Q4 2020 | $2,970,000 | +389.3% | 55,556 | +277.6% | 0.03% | +141.7% |
| Q3 2020 | $607,000 | -91.1% | 14,712 | -89.6% | 0.01% | -93.2% |
| Q2 2020 | $6,835,000 | +1864.1% | 141,006 | +1613.7% | 0.18% | +831.6% |
| Q1 2020 | $348,000 | -82.6% | 8,228 | -82.4% | 0.02% | -50.0% |
| Q4 2019 | $2,001,000 | – | 46,781 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 25,819,768 | $887,684,000 | 7.26% |
| Avoro Capital Advisors LLC | 1,630,000 | $56,039,000 | 7.16% |
| ACUTA CAPITAL PARTNERS, LLC | 572,756 | $19,691,000 | 4.67% |
| HWG Holdings LP | 100,994 | $3,472,000 | 4.38% |
| HARVEY CAPITAL MANAGEMENT INC | 230,350 | $7,919,000 | 3.56% |
| SECTORAL ASSET MANAGEMENT INC | 671,113 | $23,073,000 | 2.70% |
| Palo Alto Investors LP | 1,590,430 | $54,679,000 | 2.58% |
| Ghost Tree Capital, LLC | 350,000 | $12,033,000 | 2.24% |
| GARRISON BRADFORD & ASSOCIATES INC | 72,550 | $2,494,000 | 2.20% |
| EMORY UNIVERSITY | 56,135 | $1,930,000 | 1.82% |